Prestige Consumer Healthcare (PBH) Faces Index Removals, Is The Stock Cheap?

Index removals and fresh debt plans put Prestige Consumer Healthcare in focus

Prestige Consumer Healthcare (PBH) has drawn attention after being removed from several Russell growth indices, while its subsidiary Prestige Brands moves ahead with a new senior notes offering and a concurrent debt redemption plan.

See our latest analysis for Prestige Consumer Healthcare.

The share price of Prestige Consumer Healthcare closed at US$47.27, with a 7 day share price return of 2.65%, a 90 day share price return that fell 18.05%, and a 1 year total shareholder return that declined 41.15%. This suggests recent momentum has faded even as the index removals and fresh debt plans refocus attention on the stock.

If this shift in sentiment has you reassessing your watchlist, it could be a good moment to look beyond healthcare and check out 20 top founder-led companies

Prestige Consumer Healthcare now trades well below some valuation estimates, despite annual revenue and net income growth. The key question is whether this weakness signals mispricing or whether the market is already factoring in the company’s future.

Most Popular Narrative: 29.2% Undervalued

Prestige Consumer Healthcare’s most followed narrative anchors on a fair value of $66.80 per share, compared with the latest close at $47.27. It frames that gap using a 7.11% discount rate tied to its future earnings and cash flow profile.

Prestige’s strong and consistent free cash flow generation (~$245 million projected for the year) provides financial flexibility for continued deleveraging and opportunistic share repurchases, supporting future earnings per share (EPS) growth and value for shareholders.

Read the complete narrative.

If you want to see what sits behind that cash flow confidence and repurchase story, the narrative leans on steady revenue compounding, firmer margins, and a future earnings multiple that undercuts many sector peers.

Result: Fair Value of $66.80 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Prestige Consumer Healthcare still faces clear risks, including ongoing supply constraints in key brands and rising e commerce competition, which could pressure margins and growth expectations.

Find out about the key risks to this Prestige Consumer Healthcare narrative.

Next Steps

With both risks and rewards on the table for Prestige Consumer Healthcare, now is the time to check the underlying data and decide where you stand, starting with the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Prestige Consumer Healthcare?

Do not stop with Prestige Consumer Healthcare; broaden your opportunities by scanning other stocks that match clear, data driven criteria before the next move passes you by.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com